Share on StockTwits
 

Analysts at Cowen and Company cut their price target on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) from $105.00 to $95.00 in a research report issued to clients and investors on Friday, AmericanBankingNews.com reports. Cowen and Company’s price target indicates a potential upside of 44.44% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday, November 19th. They now have a $110.00 price target on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday, November 19th. They now have a $106.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $107.00 to $115.00 in a research note to investors on Wednesday, November 13th. They now have a “buy” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $100.82.

Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 10.82% during mid-day trading on Friday, hitting $65.77. The stock had a trading volume of 2,763,269 shares. Aegerion Pharmaceuticals has a 52 week low of $25.92 and a 52 week high of $101.00. The stock has a 50-day moving average of $68.83 and a 200-day moving average of $79.58. The company’s market cap is $1.923 billion.

Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, October 29th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. The company’s quarterly revenue was up 1629900.0% on a year-over-year basis. Analysts expect that Aegerion Pharmaceuticals will post $-1.96 EPS for the current fiscal year.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.